TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Sponsor: Beat AML, LLC · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 3000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT03013998 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03013998 Rescue Dossier →